## **Supplementary Online Content**

Weber WP, Matrai Z, Hayoz S, et al; TAXIS Study Writing Group. Association of axillary dissection with systemic therapy in patients with clinically node-positive breast cancer. *JAMA Surg*. Published online July 19, 2023. doi:10.1001/jamasurg.2023.2840

**eTable.** Logistic Regression Model for the Effect of Treatment Arm on the Administration of Adjuvant Systemic Therapy and Chemotherapy

This supplementary material has been provided by the authors to give readers additional information about their work.

**eTable.** Logistic Regression Model for the Effect of Treatment Arm on the Administration of Adjuvant Systemic Therapy and Chemotherapy

	Unadjusted		Adjusted	
	Odds ratio	95% CI	Odds ratio	95% CI
Upfront surgery setting: HR+HER2-				
Adjuvant systemic therapy	0.67	(0.24 - 1.86)	0.50	(0.15 - 1.64)
Adjuvant chemotherapy	0.74	(0.22 - 2.46)	0.72	(0.19 - 2.67)
Neoadjuvant chemotherapy				
Adjuvant systemic therapy	0.92	(0.49 - 1.75)	0.86	(0.43 - 1.70)
Adjuvant chemotherapy	1.31	(0.85 - 2.00)	1.26	(0.78 - 2.01)

Multivariable analyses adjusted for palpable vs. non-palpable disease, menopausal status, tumor subtype, grade, age, year and country.